Search clinical trials for: Icon

Total 667 results

Gannex Pharma Co., Ltd.

Completed

DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.

Healthy | NAFLD

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Safety and Pharmacokinetics of Rezafungin

Fungal Infection

United States
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)

Alagille Syndrome

France, Belgium, Poland, Australia, Spain, United Kingdom
AGO Research GmbH
ARCAGY/ GINECO GROUP; Australia New Zealand Gynaecological Oncology Group; Arbeitsgemeinschaft... and other collaborators

Completed

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Recurrent Platinum-sensitive Ovarian Cancer

France, Belgium, Germany, Australia, United Kingdom, Austria
Gannex Pharma Co., Ltd.

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
Cytokinetics

Completed

A Study of CK-1827452 Infusion in Stable Heart Failure

Heart Failure

United States, United Kingdom, Georgia, Russian Federation
Daiichi Sankyo Co., Ltd.
ICON Clinical Research

Completed

CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Iconic Therapeutics, Inc.

Terminated

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) (DECO)

Choroidal Neovascularization | Wet Macular Degeneration

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI); Rutgers Cancer Institute of New Jersey

Completed

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Prostatic Adenocarcinoma | Prostate Carcinoma Metastatic to the Bone

United States
Shanghai Mental Health Center

Unknown

Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression

Depressive Disorder

China
Steba Biotech S.A.
ICON plc; International Drug Development Institute

Completed

European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up

Cancer of the Prostate

Netherlands, Spain, France, Germany, United Kingdom, Finland, Italy, Sweden
BeyondSpring Pharmaceuticals Inc.
Covance; ICON plc

Completed

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (Protective-1)

Chemotherapy-induced Neutropenia

China, Russian Federation, United States, Ukraine
Duke University

Terminated

iControl Chronic Kidney Disease (iControl CKD)

Chronic Kidney Diseases

United States
Bayer
Nerre Therapeutics Ltd.

Completed

Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms (RELENT-1)

Post-menopausal Vasomotor Symptoms

United States
Brigham and Women's Hospital
Icahn School of Medicine at Mount Sinai; The Miriam Hospital; Indiana University

Completed

The ICON Study: Outcomes After FMT for Patients With IBD and CDI

Inflammatory Bowel Diseases | Clostridium Difficile Infection

United States
Poitiers University Hospital

Unknown

Long Term Effect of Bariatric Surgery on Pelvic Floor Disorders (ICONES)

Weight Loss | Bariatric Surgery Candidate

France
University of North Carolina, Chapel Hill
Robert Wood Johnson Foundation

Completed

Designing Impactful Warnings for Sugary Drinks

Health Behavior

United States
Theravance Biopharma

Completed

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Healthy

United States
Theravance Biopharma

Completed

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Constipation

United States
Theravance Biopharma

Completed

TD-6450 SAD and MAD in Healthy Subjects

Hepatitis C

United States
Novartis Pharmaceuticals

Terminated

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Hypertension

United States
Imam Abdulrahman Bin Faisal University

Unknown

Performance of Different Resin Infiltration Materials on White Spot Lesions: Clinical and Laboratory Assessments

White Spot Lesion

Saudi Arabia
Iconic Therapeutics, Inc.

Completed

Safety and Tolerability Study for Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
Ardeypharm GmbH
ICON plc; Clinscience Sp. z o.o.

Completed

E. Coli Nissle 1917 - Suspension for Infection Prophylaxis (RONi)

Infections

Germany, Poland
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
LEO Pharma

Completed

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

Psoriasis Vulgaris

United States, United Kingdom, Canada, Germany
Iconic Therapeutics, Inc.

Completed

Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma

Uveal Melanoma | Choroid Neoplasm

United States
RAI Services Company
ICON Clinical Research Limited

Completed

CSD1805: Study to Assess Nicotine Uptake and Product Use Behavior in Moist Snuff Consumers Using Two Moist Snuff Products

Tobacco Use

United States
Iconic Therapeutics, Inc.

Completed

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (EMERGE)

Age-related Macular Degeneration | Choroidal Neovascularization

United States
OncoMed Pharmaceuticals, Inc.
Celgene Corporation

Completed

A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer (DENALI)

Nonsquamous Nonsmall Cell Neoplasm of Lung

Spain, United States, Australia, Italy, Belgium
Actinogen Medical
ICON plc

Completed

Xanamem™ in Healthy Elderly Subjects (XanaHES)

Cognitive Function | Peripheral Neuropathy | Electrocardiography | Central Nervous System | Safety | Healthy Ageing | Cortisol | Cerebrospinal Fluid | Small Fibre Neuropathy

Australia
Celgene

Completed

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

Healthy Volunteers

United States
Ixchelsis Limited
HealthCore-NERI; Novotech (Australia) Pty Limited; ICON plc; PHT Corporation

Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

Premature Ejaculation

United States, Australia
Clovis Oncology, Inc.

Terminated

Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Korea, Republic of, Germany, Taiwan, Australia, Hong Kong, Netherlands, Spain, France, United Kingdom, Canada, Switzerland
Atridia Pty Ltd.

Completed

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

Prostate Cancer | Neoplasm

Australia
Daiichi Sankyo Co., Ltd.
ICON Clinical Research

Completed

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Fisher and Paykel Healthcare
University Hospital, Angers; University Hospital, Grenoble

Completed

Evaluation of APAP With SensAwake in OSA and Insomnia Patients

Insomnia | Obstructive Sleep Apnea

France
Amgen

Completed

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

Healthy Volunteers

United States
Stealth BioTherapeutics Inc.
ICON Clinical Research

Completed

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events (EMBRACE)

Reperfusion Injury | STEMI

United States, Hungary, Germany, Poland
National Taiwan University Hospital

Completed

Non-invasive Monitor in Endoscopic Invasive Procedure

Cholangiopancreatography, Endoscopic Retrograde | Endoscopic Ultrasonography

Taiwan
Boston Children's Hospital
Terrana ITP Research Fund

Completed

ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP (ICON1)

Immune Thrombocytopenia

United States, Canada
Proteostasis Therapeutics, Inc.

Completed

Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

Cystic Fibrosis | Healthy Volunteer

United States, Canada, Denmark, Germany, Sweden
Reven Pharmaceuticals, Inc.
ICON plc; ERT: Clinical Trial Technology Solutions

Completed

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

Critical Limb Ischemia

United States
Proteostasis Therapeutics, Inc.

Completed

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Healthy Volunteer - Complete | Cystic Fibrosis - Complete

United States, Belgium, United Kingdom, France, Germany, Canada, Denmark, New Zealand, Australia
Kazia Therapeutics Limited

Completed

Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States, Australia
Cyclerion Therapeutics

Completed

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Hypertension | Diabetes Mellitus, Type 2

United States
Danisco
ICON plc; 4Pharma Ltd.; Daacro

Completed

A Study to Assess the Safety and Efficacy of Probiotic to Modulate Psychological Stress

Healthy | Stress, Psychological

Ireland, United Kingdom
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

Prostate Cancer

Canada, United States, Spain, Australia, Denmark, Korea, Republic of, Belgium, Singapore, Finland, Netherlands, France, Austria, Germany, Israel, United Kingdom, Italy, Japan, Lithuania, Poland, Russian Federation, Slovakia, Sweden
Sucampo Pharma Americas, LLC
Takeda

Completed

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

Healthy Volunteers

United States

Search clinical trials for: Icon

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations